Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026
Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026
Company Deals

Specialised Therapeutics to Commercialize Akeso’s PD-1 Inhibitor Penpulimab in APAC

Fineline Cube Apr 12, 2023

Singapore-based Specialised Therapeutics Asia Pte Ltd (ST) has been appointed to handle the commercialization of...

Company

Legend Biotech Appoints Dr. Mythili Koneru as Chief Medical Officer to Lead Clinical Development

Fineline Cube Apr 12, 2023

China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced the appointment of Dr. Mythili Koneru as...

Company Drug

Luye Pharma’s Bevacizumab Biosimilar Accepted for Review in Brazil by ANVISA

Fineline Cube Apr 12, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that the market approval filing for its...

Policy / Regulatory

Round 8 VBP Tender Results: RMB 3.775 Billion Awarded Across 152 Manufacturers

Fineline Cube Apr 12, 2023

The official results of Round 8 of China’s national Volume-Based Procurement (VBP) tender program have...

Company Drug

Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE

Fineline Cube Apr 12, 2023

The Center for Drug Evaluation (CDE) website has indicated that Huahui Health’s HH-003, Boehringer Ingelheim’s...

Company Drug

Bristol-Myers Squibb Launches Zeposia in China for Multiple Sclerosis Treatment

Fineline Cube Apr 11, 2023

Global pharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced the market launch in China...

Policy / Regulatory

Hubei Implements Inter-Provincial VBP Tender Results for Pacemakers

Fineline Cube Apr 11, 2023

The Hubei provincial Drug and Instrument Procurement Platform has issued a notice regarding the implementation...

Company Drug

Zelgen Biopharmaceuticals’ ZG006 Earns FDA Approval for Small-Cell Lung Cancer Trial

Fineline Cube Apr 11, 2023

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical trial approval from...

Company Drug

JW Therapeutics’ Carteyva Receives NMPA Approval for Moderate-to-Severe SLE Clinical Trial

Fineline Cube Apr 11, 2023

China-based JW Therapeutics (HKG: 2126) has announced receiving tacit clinical trial approval from the National...

Company Deals Digital

Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China

Fineline Cube Apr 11, 2023

China-based Hua Medicine (HKG: 2552) has announced a sales and distribution agreement with online pharma...

Company

CStone Pharmaceuticals Reduces Ayvakit Price to Boost Accessibility in China

Fineline Cube Apr 11, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced a lower recommended price for its precision medicine...

Company Deals

Hangzhou Baikai Biomedical and Leads Biolabs Partner to Develop Innovative ADCs

Fineline Cube Apr 11, 2023

China-based Hangzhou Baikai Biomedical Co., Ltd and Leads Biolabs Inc. have announced a partnership aimed...

Hospital Policy / Regulatory

NHC Report: Performance Assessment of National Class 2 Public Hospitals in 2021

Fineline Cube Apr 11, 2023

The National Health Commission (NHC) has released the “Report on the National Monitoring and Analysis...

Company Deals

Cuban-Chinese Biotechnology Center Showcases Drug and Vaccine Progress to Cuban Delegation

Fineline Cube Apr 11, 2023

Researchers from Cuba and China at the Yongzhou joint biotechnology innovation center in China’s Hunan...

Medical Device Policy / Regulatory

Hebei Leads Sanming Alliance in Launching 8th VBP for 19 Medical Consumables

Fineline Cube Apr 11, 2023

The Hebei medical drug and device centralized procurement center has announced the start of the...

Company Drug

Takeda Pharma’s Iclusig Poised for Priority Review by CDE for Leukemia Treatments

Fineline Cube Apr 11, 2023

The Center for Drug Evaluation (CDE) website has indicated that Takeda Pharma’s (TYO: 4502) Iclusig...

Company Deals

Arctic Vision Partners with Sinopharm Group for Ophthalmic Product Distribution in China

Fineline Cube Apr 11, 2023

China-based ophthalmology specialist Arctic Vision has entered into a strategic partnership with Sinopharm Group Distribution...

Drug Policy / Regulatory

FDA Issues Complete Response Letters to Six Novel Drugs in Q1 2023

Fineline Cube Apr 10, 2023

According to an analysis, the US FDA issued complete response letters (CRLs) to six novel...

Company Deals

Bioyond Robotics Secures $29 Million in Series A and A+ Financing Rounds

Fineline Cube Apr 10, 2023

Bioyond Robotics, a Shanghai-based intelligent automation company, has reportedly raised around RMB 200 million (USD...

Policy / Regulatory

Henan Province Sees 53.6% Price Reduction in Neuro and Peripheral Intervention Consumables Tender

Fineline Cube Apr 10, 2023

The Henan Province Public Resources Trading Center has released a notification regarding the completion of...

Posts pagination

1 … 533 534 535 … 660

Recent updates

  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.